## I BA'<95 @H<'G7=9B79G'79BH9F'DFCDCG5 @85H5'G<99H'fD8GL'fHBH9FB5@IG9'CB@ML'

PROPOSAL # HSC-	89D5FHA9BH (Lead department if multiple departments)						D=g"CF; '7C89' 7I			F9BH: I B8 ( <sup>*</sup>			
								@wujcb'Ë'Cb'	icb ECb 7 Ua di gzunless PI certifies one of these choices ue				
DF-B7-D5 @-BJ9GH-; 5HCF fD± 89; F99			(						eased facility where rent/utilities & maintenance is charged to				
				M9 G <sup>°</sup>				proposed program					
7 C!D≕fkZa cfY'h\ Ub'cbYžUłhUW' g\ YYkŁ' 7 c!D≕Bg' 89; F99 <u>≕</u>			= 'M9G'5	<u>: ™9G'56CJ9.</u> HC'IE				In a facility made available at <b>BC!7 CGH</b> to the program by a Non- University Organization					
			: F	:FCA'IBA' 6CH<'K5MG'				® VVHjcb					
89D5FHA9BH7CBH57H	FHA9BH'D <cb9' department="" email<="" td=""></cb9'>												
GDCBGCF.'fU[ YbWn#Wta dUbn#Wt"UVcfUrcft				GC @7 ±15 H±CB"BI A69F"cf"DFC; F5 A'B5 A9					85 H9 'DF CDCG5 @=G'81 9 'HC'5; 9B7 M.'				
5; 9B7M7CBH57H				5; 9B7M9!A5=@						5; 9B7MTH9@D <cb9< td=""></cb9<>			
DFC>97H'HH@ fBc'5VVfYj ]Ui]cbg'Ë+) '7\ UfUWfNf'@a ]lt.													
OfcdcgU 'HndY' SELECT ONE) SUPPLEMENT				TRANSFER				7 CCHC. 24; "PIRIT, "4; DAY", "E! AL ARIDANI"					
(SELECT ONE)		<b>□\</b> \/\/\	FROM					7 CGHG'Zcf'=b]h U'cf'BYk'6i X  YhDYf cX.					
NEW NON COMPETE	EWAL	FROM					From To DIRECT COSTS \$						
NON-COMPETE							DIRECT COSTS \$ F&A RATE %						
<b>-BGHFIA9BH</b> "HMD9." (Sele	71117	00 51	<b>7000</b>					-	<del></del> \$				
GRANT	DATI\/E A							A COSTS \$					
CLINICAL TRIAL	COOPERATIVE AGREEMENT CLINICAL TRIAL - SUBAWARD								TICID	ET OT AL HIDTIJOA			
CONTRACT	iginating sponsor (i.e. NIH, HRSA, FDA, etc)												
CONTINUE	Name of originating						,, ,	i Brt, Gto)					
CLINICAL TRIALS	<u> </u>		<del></del>	-		<del>-</del>		<del> </del>		_		<u> </u>	
ONLY:	FDA I	Phase:	<u> </u>	II		or		IV	M	ulti Center Study	YES	NO	
Enrollment Start Date: Inventions are Anticipated				YES NO PI Waives Intellec					tual Property Ownership YES NO				
: 571 @HM/57H⇒J+HM/85H565G9 ft 58ŁËGCA / '7CD'CB@M'fG9 @97H'CB9Ł													
RESEARCH		CLINICA						UCATION			MISSION SPEC	CIFIC	
8 C9 G'H< =G'DF C>97 H'G	:5A9F <i>⊒</i>	₹5BG <=GD5B₹G					CHc9F'I B89FG9FJ98'DCDI @HCBG						
⇒ 'Hx-±G'DFCDCG5 @±BJC @/9 G''±H9 A G'@×GH98 '69 @CK ž7<97?'5 @@6CLf9 GL'Hx5 H'5 DD@M													
HUMAN SUBJECTS	RECOMBINANT DNA; RADIOACTIVE/HAZARDOUS MATERIALS or WASTE – Contact Safety Officer												
LABORATORY ANIMA	<u>LABORATORY ANIMALS</u> <u>EXPORT CONTROL</u> / <u>SELECT AGENTS</u>												
SUBCONTRACTORS				FOREIGN NATIONAL OR DUAL CITIZENSHIP OF ANY UNM PERSONNEL									
CONSULTANTS				FOREIGN COLLABORATORS  PROTEIGN COLLABORATORS									
VA EMPLOYEES-MOU NEEDED (NIH)				RESTRICTIONS ON PUBLICATIONS  FUNDING from a FOREIGN OWNER A CENCY/COMPANY, List Country									
HSC F&A SPLIT HSC/MAIN SPLIT				FUNDING from a FOREIGN-OWNED AGENCY/COMPANY, List Country  FOREIGN TRAVEL List Country									
COST SHARE OF MATCHING FUNDS FOREIGN TRAVEL, List Country:  DECOMPLEY OF SENSITIVE INFORMATION  DECOMPLEY OF SENSITIVE INFORMATION													

Additional Project Personnel List